Glaucoma is the major cause of irreversible blindness throughout the world. Of all of the treatments that are available at present, the most effective appears to be surgery; however, excessive conjunctival scarring can lead to surgical failure. In the last decade, the introduction of the anti-metabolites mitomycin-C and 5-fluorouracil as anti-scarring treatments have greatly improved the results of glaucoma surgery, but these agents are associated with complications that can potentially result in blindness. A possible target for a more physiological approach to anti-scarring is transforming growth factor β. This review examines the role of transforming growth factor β in conjunctival scarring and discusses promising new ways of modifying its activity.
Skip Nav Destination
Article navigation
Review Article|
January 17 2003
Role of transforming growth factor β in conjunctival scarring
M. Francesca CORDEIRO
1Department of Pathology, Moorfields Eye Hospital and Institute of Ophthalmology, Bath Street, London EC1V 9EL, U.K., and Department of Glaucoma, Moorfields Eye Hospital and Institute of Ophthalmology, Bath Street, London EC1V 9EL, U.K.
Correspondence: Dr Francesca Cordeiro (e-mail [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Online ISSN: 1470-8736
Print ISSN: 0143-5221
The Biochemical Society and the Medical Research Society © 2003
2003
Clin Sci (Lond) (2003) 104 (2): 181–187.
Connected Content
A correction has been published:
Role of transforming growth factor β in conjunctival scarring
Citation
M. Francesca CORDEIRO; Role of transforming growth factor β in conjunctival scarring. Clin Sci (Lond) 1 February 2003; 104 (2): 181–187. doi: https://doi.org/10.1042/cs1040181
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Cited By
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |